Antioxidants for Alzheimer Disease

Galasko, Douglas; Peskind, Elaine R.; Clark, Christopher M.; Quinn, Joseph F.; Ringman, John M.; Jicha, Gregory A.; Cotman, Carl W.; Cottrell, Barbara A.; Montine, Thomas J.; Thomas, Ronald G.; Aisen, Paul S.

doi:10.1001/archneurol.2012.85

Cited by 317 publications

(135 citation statements)

References 39 publications

Supporting

Mentioning

133

Contrasting

Order By: Relevance

“…ADLs were measured in 55 trials, using 12 measures. 27,28,33,37,41,45,46,49,51,52,54,55,57,59,61,63,64,66,68,77,78,81,[85][86][87][88][89][90]92,97,104,[106][107][108][110][111][112]114,115,118,119,[121][122][123][124][125]128,134,135,137,138,[142][143][144][145] Biological markers were measured in 51 trials using a variety of nine biological t...…”

Section: Published Trialsmentioning

confidence: 99%

Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations

Webster

Groskreutz

Grinbergs-Saull

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

Background: There is currently no disease-modifying treatment available to halt or delay the progression of the disease pathology in dementia. An agreed core set of the best-available and most appropriate outcomes for disease modification would facilitate the design of trials and ensure consistency across disease modification trials, as well as making results comparable and meta-analysable in future trials. Objectives: To agree a set of core outcomes for disease modification trials for mild to moderate dementia with the UK dementia research community and patient and public involvement (PPI). Data sources: We included disease modification trials with quantitative outcomes of efficacy from (1) references from related systematic reviews in workstream 1; (2) searches of the Cochrane Dementia and Cognitive Improvement Group study register, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, EMBASE, Latin American and Caribbean Health Sciences Literature and PsycINFO on 11 December 2015, and clinical trial registries [International Standard Randomised Controlled Trial Number (ISRCTN) and clinicaltrials.gov] on 22 and 29 January 2016; and (3) hand-searches of reference lists of relevant systematic reviews from database searches. Review methods: The project consisted of four workstreams. (1) We obtained related core outcome sets and work from co-applicants. (2) We systematically reviewed published and ongoing disease modification trials to identify the outcomes used in different domains. We extracted outcomes used in each trial, recording how many used each outcome and with how many participants. We divided outcomes into the domains measured and searched for validation data. (3) We consulted with PPI participants about recommended outcomes. (4) We presented all the synthesised information at a conference attended by the wider body of National Institute for Health Research (NIHR) dementia researchers to reach consensus on a core set of outcomes. Results: We included 149 papers from the 22,918 papers screened, referring to 125 individual trials. Eighty-one outcomes were used across trials, including 72 scales [31 cognitive, 12 activities of daily living (ADLs), 10 global, 16 neuropsychiatric and three quality of life] and nine biological techniques. We consulted with 18 people for PPI. The conference decided that only cognition and biological markers are core measures of disease modification. Cognition should be measured by the Mini Mental State Examination (MMSE) or the Alzheimer’s Disease Assessment Scale – Cognitive subscale (ADAS-Cog), and brain changes through structural magnetic resonance imaging (MRI) in a subset of participants. All other domains are important but not core. We recommend using the Neuropsychiatric Inventory for neuropsychiatric symptoms: the Disability Assessment for Dementia for ADLs, the Dementia Quality of Life Measure for quality of life and the Clinical Dementia Rating scale to measure dementia globally. Limitations: Most of the trials inclu...

show abstract

Section: Published Trialsmentioning

confidence: 99%

Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations

Webster

Groskreutz

Grinbergs-Saull

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Recent studies have shown the CoQ 10 to be neuroprotective in various conditions but mostly in in vitro and in vivo animal models (as reviewed by Bonda et al 2010, andWallen 2010), as until now the only clinical trial with CoQ 10 monotherapy was a double-blind, placebo controlled study on AD patients (N=78) treated 16 week with or with 400 mg of CoQ 10 3 times/d, in which no effect on cognition and cerebrospinal antioxidant biomarkers were found (Galasko et al 2012). Additionally, a synthetic variant of CoQ 10 , idebenone, has been tested in clinical trials in which inconsistent results were obtained; better cognitive score in with 90 -120 mg doses only (Gutzmann et al 1998;Weyer et al 1997) and no effect with even higher doses in another trial .…”

Section: Compounds With Predominant Antioxidative Activity Often Accmentioning

confidence: 99%

“…In a placebo-controlled trial, vitamin E (2000 IU/day, 2 years) alone slowed (-53%) functional deterioration in patients with moderate AD while in combination with vitamin C it reduced prevalence (-78%) and incidence (-64%) of AD (Kontusch and Schekatolina, 2004). However, recent double-blind, placebo controlled study on AD patients (N=78) treated 16 week with a combination of 800 IU/d of vitamin E plus 500 mg/d of vitamin C plus 900 mg/d of α-lipoic acid (E/C/ALA) demonstrated that E/C/ALA treatment combination accelerated the cognitive decline although the cerebrospinal fluid F-2-isoprostane levels, which represented the oxidative stress biomarker, decreased by 19% from baseline (Galasko et al 2012). …”

Section: Compounds With Predominant Antioxidative Activity Often Accmentioning

confidence: 99%

What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research

et al. 2012

View full text Add to dashboard Cite

“…These subtle benefits must be confirmed in the population subgroup that took gingko biloba extract for at least 4 years (20). Additional studies have further investigated the effectiveness of nutrients, including omega 3 fatty acids, DHA, vitamin E, vitamin C, and coeznyme Q, using more specific neuropsychologic measures and CSF biomarkers as outcomes, with little success (21–23). Two trials that have shown apparent benefits tested an oral ketogenic compound, AC-1202, in subjects with probable AD (24) and a medical food called Souvenaid® in subjects with mild AD (25).…”

Section: The Role Of Food In Maintaining or Improving Cognitive Functmentioning

confidence: 99%

How to design nutritional intervention trials to slow cognitive decline in apparently healthy populations and apply for efficacy claims: A statement from the international academy on nutrition and aging task force

Ferry

Coley

Andrieu

et al. 2013

The Journal of nutrition, health and aging

View full text Add to dashboard Cite

Interventions are crucial as they offer simple and inexpensive public health solutions that will be useful over the long term use. A Task Force on designing trials of nutritional interventions to slow cognitive decline in older adults was held in Toulouse in September 2012. The aim of the Task Force was to bring together leading experts from academia, the food industry and regulatory agencies to determine the best trial designs that would enable us to reach our goal of maintaining or improving cognitive function in apparently healthy aging people. An associated challenge for this Task Force was to determine the type of trials required by the Public Food Agencies for assessing the impact of nutritional compounds in comparison to well established requirements for drug trials. Although the required quality of the study design, rationale and statistical analysis remains the same, the studies designed to show reduction of cognitive decline require a long duration and the objectives of this task force was to determine best design for these trials. Two specific needs were identified to support trials of nutritional interventions: 1- Risk- reduction strategies are needed to tackle the growing burden of cognitive decline that may lead to dementia, 2- Innovative study designs are needed to improve the quality of these studies.

show abstract

Antioxidants for Alzheimer Disease

Cited by 317 publications

References 39 publications

Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations

Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations

What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research

How to design nutritional intervention trials to slow cognitive decline in apparently healthy populations and apply for efficacy claims: A statement from the international academy on nutrition and aging task force

Contact Info

Product

Resources

About